Newsroom | 2039 results

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fiscal 2026” or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year)....

IRVINE, Calif.--(BUSINESS WIRE)--WM Technology, Inc. (“WM Technology” or the “Company”) (OTC: MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced its financial results for the first quarter ended March 31, 2026. “We are encouraged by the recent rescheduling of medical cannabis, which represents a meaningful federal step forward for the industry and for the millions of patients who rely on medical cannabis,” said Doug Francis, CEO and Chairman...

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today provided an update on its application under the Texas Compassionate Use Program (TCUP). The Texas Department of Public Safety (DPS) has announced a retroactive correction to the tabulation methodology used in its conditional license selection process, impacting multiple applicants. Under the corrected tabulation, the conditional license previously awarded and publicly announced...

CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports First Quarter 2026 Financial Results...

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targete...

SAN DIEGO--(BUSINESS WIRE)--Innovative Industrial Properties, Inc. (IIP) (NYSE: IIPR) announced today it has closed on a $56.5 million secured term loan (the “Loan”). The Loan has an initial term of three years, bears interest at the one-month Secured Overnight Financing Rate (SOFR) plus a spread of 500 basis points, is interest only and is secured by certain properties of the Company. The proceeds from the Loan are expected to be used to pay off the Company’s unsecured notes that are maturing...

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use t...

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Aberdeen, located in Aberdeen, Ohio. This marks the Company's second Ohio dispensary opening in the past month, increasing its footprint to eight locations statewide and 74 nationally. “Sunnyside Aberdeen is our second dispensary opening in the state in a month, reflecting our commitment to serving more communities across Ohio,” said Cha...

NEW YORK--(BUSINESS WIRE)--Nabis acquires Hudson Distribution's New Jersey cannabis license and warehouse lease, gaining turnkey infrastructure to launch in the Garden State....

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell in response to the Department of Justice’s final rule publication rescheduling medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. “Rescheduling medical cannabis is a long-overdue step that finally brings federal policy closer to the science. For the first time in history, our fed...